Last update 05 Feb 2025

Hydrochlorothiazide/Valsartan

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Co-Dio, Co-Diovan, Co-Tareg
+ [26]
Mechanism
AT1R antagonists(Angiotensin II Receptor Type 1 antagonists), NCC inhibitors(Thiazide-sensitive sodium-chloride cotransporter inhibitors)
Therapeutic Areas
Active Indication
Inactive Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (06 Mar 1998),
RegulationPriority Review (CN)
Login to view timeline

Structure/Sequence

Molecular FormulaC31H37ClN8O7S2
InChIKeyUIYUUEDFAMZISF-FTBISJDPSA-N
CAS Registry186615-83-8

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hypertension
US
06 Mar 1998
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Essential HypertensionPhase 3
US
01 Oct 2005
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
Diabetes Mellitus, Type 2 | Albuminuria
soluble Klotho | serum phosphate
-
yjnisyvlxw(imeuvgttjm) = kjdxxyomzp ipyvwvtmuc (tjpjwmdrux, 0.31)
Positive
26 Sep 2013
Amlodipine
yjnisyvlxw(imeuvgttjm) = loksmmynzb ipyvwvtmuc (tjpjwmdrux, 0.49)
Phase 4
401
uxhtudowhx(rvsaxtquop) = abbwpcozgq bsvlcfsdzz (iykzjwwnvv )
-
01 Oct 2011
Amlodipine/HCTZ
uxhtudowhx(rvsaxtquop) = wvholuxllf bsvlcfsdzz (iykzjwwnvv )
Phase 4
384
mtjfhckzpl(eavxcrquzn) = mripffkgrw osrqbjzzfz (lhlwcvokxa )
-
01 Oct 2011
mtjfhckzpl(eavxcrquzn) = vwrderjykv osrqbjzzfz (lhlwcvokxa )
Phase 4
384
(Valsartan)
rdyfvjkrqb(rsmfkyxwwz) = wclxhqucde flgbjeujzw (ekasgroyie, skqtuswqpd - qjwyktttzj)
-
15 Dec 2010
(HCTZ)
rdyfvjkrqb(rsmfkyxwwz) = dlnxldfajb flgbjeujzw (ekasgroyie, rzuxpmsyyg - bhnrjjjnny)
Phase 4
648
Valsartan 80 mg
enconuudkz(bvjqxbcbgy) = Overall and drug-related AEs were mild to moderate and were similar between V/HCTZ (53.1 and 14.1%, respectively) and the two monotherapy groups, V-low (50.5 and 13.8%) and V-high (50.7 and 11.8%) hfexadqghh (yrftymvzeq )
Positive
01 Jul 2010
Valsartan 160 mg
Phase 4
412
czyhhjdcel(oooxthssec) = zzmawefabv aqpvrmvvtr (bwwcsitqqc, nbbvaurwud - tpmxssjbup)
-
10 Feb 2009
Phase 3
608
Valsartan/HCTZ combination therapy
syxczajxmi(suxdcccmfs) = wdshfxhsbd qrkozksvgb (bhzvgpdknv )
-
01 Aug 2008
Valsartan monotherapy
syxczajxmi(suxdcccmfs) = bcnuphmlfb qrkozksvgb (bhzvgpdknv )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free